Table 3.
Clinical parameters associated with significant fibrosis in the training group (138 patients)
| No significant fibrosis (n = 64) | Significant fibrosis (n = 74) | P value | ||
| Age (yr) | 39.88 ± 9.68 | 39.61 ± 9.37 | 0.260 | |
| Gender | Male | 47 (73.4%) | 54 (73.0%) | 0.951 |
| Female | 17 (26.6%) | 20 (27.0%) | ||
| CP (mg/L) | 231.22 ± 35.26 | 196.73 ± 42.27 | < 0.0001 | |
| Total bilirubin (μmol/L) | 13.11 ± 6.97 | 13.48 ± 6.05 | 0.747 | |
| Albumin (g/L) | 44.27 ± 3.29 | 41.79 ± 3.75 | <0.0001 | |
| Globulin (g/L) | 27.15 ± 5.15 | 31.35 ± 5.03 | 0.363 | |
| ALT (IU/L) | 29.25 ± 10.32 | 30.00 ± 9.17 | 0.652 | |
| AST (IU/L) | 25.77 ± 7.21 | 27.53 ± 7.11 | 0.152 | |
| GGT (IU/L) | 23.69 ± 13.96 | 33.90 ± 29.78 | 0.017 | |
| TCHO (mmol/L) | 4.82 ± 0.83 | 4.44 ± 0.62 | 0.004 | |
| TG (mmol/L) | 1.31 ± 0.74 | 1.21 ± 0.85 | 0.474 | |
| CHE (IU/mL) | 9254.48 ± 2583.76 | 7710.21 ± 1903.41 | < 0.0001 | |
| WBC (109/L) | 5.78 ± 1.36 | 5.71 ± 1.59 | 0.766 | |
| PLT (109/L) | 212.63 ± 50.24 | 177.49 ± 47.94 | < 0.0001 | |
| HBsAg (Log IU/mL) | 4.40 ± 0.78 | 3.45 ± 0.96 | < 0.0001 | |
| HBV-DNA (Log IU/mL) | 5.17 ± 2.33 | 5.00 ± 1.70 | 0.614 | |
| PT (s) | 11.71 ± 2.81 | 12.33 ± 2.31 | 0.161 | |
| INR | 0.96 ± 0.23 | 1.02 ± 0.19 | 0.103 | |
CP: Ceruloplasmin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma glutamyl transpeptidase; TCHO: Total cholesterol; TG: Triglyceride; CHE: Cholinesterase; WBC: White blood cell count; PLT: Platelet count; HBV: Hepatitis B virus; PT: Prothrombin time; INR: International normalized ratio.